Bot Chart, page-3012

Yep, UK company further along in development and running studies in US. They are running large Phase 2B study in actual infected surgery patients and following for 30 days after which is a high bar to cross. That study has been running for 1 year already and expected to run another 6 months assuming there is no impact from COVID-19. Their product is a new chemical entity so it gets longer patent exclusivity plus it has the same QIDP designation as ours. We can watch them to see what interest big PHARMA has in this space. We have some distance to close for the development timeline however since the marketing exclusivity only goes to the first approved product which likely explains the rationale for jumping ahead with Phase 2 study.